Disease Landscape and Forecast Insights

According to DRG epidemiology, more than 35 million people in the United States suffer migraines, and more than 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a core…

According to DRG epidemiology, more than 35 million people in the United States suffer migraines, and more than 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a…

The triptan drug class dominates the prescription acute treatment migraine market, particularly now that the class is almost fully generic. Despite the array of approved treatment options, new…

The migraine market consists of a multitude of therapies that either acutely treat migraine attacks or serve as prophylactic treatment. Among acute antimigraine therapies, triptans and NSAIDs/…

The acute migraine market is dominated by the oral triptans, although genericization of these agents as well as approvals in recent years of multiple non-oral triptans and non-triptans have begun…

For migraine patients who suffer from 15 or more migraine days per month (chronic migraine) and/or those patients who suffer from long-lasting migraine attacks or do not experience sufficient…

For the estimated 36 million people in the United States who experience migraines, multiple prescription therapies are available that have proved effective in acutely treating migraine pain and its…

Migraine, estimated to affect 36 million people in the United States, is a disabling disease characterized by unilateral or bilateral headache pain that may be accompanied by aura and the…

Last Updated 4 December 2014 The migraine market consists of a multitude of therapies that either acutely treat migraine attacks or serve as prophylactic treatment. Among acute antimigraine…

For the estimated 35 million people in the United States who experience migraines, multiple prescription therapies are available that have proved effective in acutely treating migraine pain and its…